Executive Series - Bionomics (BNO) CEO & Managing Director, Deborah Rathjen
CommSec
Online Stockbroker
Tom Piotrowski speaks with Bionomics (BNO) CEO & Managing Director, Deborah Rathjen about clinical trial results of its anxiety drug BNC210 and its Phase 2 trial for managing Post Traumatic Stress Disorder (PTSD)
To view more Executive Series interviews, visit: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful trading tools including alerts, conditional orders, stock screeners and comparison charts.
2 topics
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
Buy Hold Sell: 2 standout ASX names for FY26
Livewire Markets
Commodities
Central banks are doubling down on gold - should you?
Livewire Markets